Vitiligo Following Dupilumab Therapy for Moderate-to-Severe Atopic Dermatitis: A Case Report with Insight into Type 1/Type 2 Immune Imbalance
Clinical, Cosmetic and Investigational Dermatology · 2026-11 · Volume 19 · 1-5
DOI: 10.2147/ccid.s643447 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical, Cosmetic and Investigational Dermatology, 2026-11. Verfasst von Xiaopan Gong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Fuzhou First General Hospital (Dermatology), Fuzhou, Fujian, 350001, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Fuzhou First General Hospital (Dermatology), Fuzhou, Fujian, 350001, People's Republic of China.
Zitieren
APA
Gong, X., Chen, J., Jiang, J., & Mei, Q. (2026). Vitiligo Following Dupilumab Therapy for Moderate-to-Severe Atopic Dermatitis: A Case Report with Insight into Type 1/Type 2 Immune Imbalance. Clinical, Cosmetic and Investigational Dermatology, Volume 19, 1-5. https://doi.org/10.2147/ccid.s643447
Vancouver
Gong X, Chen J, Jiang J, Mei Q. Vitiligo Following Dupilumab Therapy for Moderate-to-Severe Atopic Dermatitis: A Case Report with Insight into Type 1/Type 2 Immune Imbalance. Clinical, Cosmetic and Investigational Dermatology. 2026;Volume 19:1-5. doi:10.2147/ccid.s643447
BibTeX
@article{Gong2026,
author = {Gong, Xiaopan and Chen, Jing and Jiang, Ju and Mei, Qin},
title = {Vitiligo Following Dupilumab Therapy for Moderate-to-Severe Atopic Dermatitis: A Case Report with Insight into Type 1/Type 2 Immune Imbalance},
journal = {Clinical, Cosmetic and Investigational Dermatology},
year = {2026},
volume = {Volume 19},
pages = {1--5},
doi = {10.2147/ccid.s643447}
}
EUVIMED